TLX

Insider Trades

Name	Value	Action	Price	Current Price
Behrenbruch ChristianDirector, Officer: MD & Group CEO $497k33.4k shares BuyApr 29, 2026 $14.87 --
Behrenbruch ChristianDirector, Officer: MD & Group CEO $500k34.5k shares BuyApr 28, 2026 $14.48 --

News

globenewswire.comTelix and United Imaging Announce Strategic Theranostics Collaborationglobenewswire.comJun 2

globenewswire.comProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026globenewswire.comJun 1

globenewswire.comTelix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferencesglobenewswire.comMay 27

seekingalpha.comTelix Pharmaceuticals: PSMA Radiopharmaceutical Player Is Revving Upseekingalpha.comMay 18

globenewswire.comIPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosingglobenewswire.comMay 18

Trade TLX

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited (TLX) is a commercial-stage biopharmaceutical entity specializing in the creation and distribution of advanced radiopharmaceuticals. Its core mission is to develop both diagnostic agents and therapeutic treatments for cancer and rare diseases across key international markets, including Australia, Belgium, Japan, Switzerland, and the United States. Among its currently available products, Telix offers Illuccix, designed for the management of prostate cancer, and TLX66-CDx, which serves as an imaging agent for osteomyelitis. The company also maintains a robust pipeline of investigational candidates aimed at various conditions: Prostate Cancer: TLX591, a radio antibody-drug conjugate, and TLX592, a candidate for targeted alpha therapy. Renal (Kidney) Cancer: TLX250-CDx, intended for both diagnosis and treatment, and TLX250, specifically for clear cell renal cell carcinoma. Brain Cancer: This includes TLX101-CDx and TLX101, which targets glioblastoma. Bone Marrow Conditioning: TLX66-CDx and TLX66 are being explored. Soft Tissue Sarcoma: TLX300-CDx and TLX300 are under development for diagnosis and treatment. Founded in 2015, Telix Pharmaceuticals Limited is based in North Melbourne, Australia.

CEO: Christian Behrenbruch
IPO Date: Nov 14, 2024

Market Data

Volume: 95.2K

Valuation

Market Cap: $3.1B

Financials

Financial statement snapshot is not available yet.

Events

EarningsAug 20

EPS est. 0.0114